The use of nanocarriers in acute myeloid leukaemia therapy: Challenges and current status

Current Pharmaceutical Biotechnology

Volumn 17, Issue 1, 2016, Pages 30-41

  Sauvage, Félix ^a   Barratt, Gillian ^a   Herfindal, Lars ^b   Vergnaud Gauduchon, Juliette ^a  

^a UNIV PARIS SUD   (France)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Acute myeloid leukaemia; AraC; Daunorubicin; Drug carriers; Drug targeting; Liposomes; Nanoparticles; Theranostics; Therapy

Indexed keywords

CYTARABINE PLUS DAUNORUBICIN; DOXORUBICIN; FOLATE RECEPTOR; GROWTH FACTOR; LIPOPROTEIN; LIPOSOME; MACROGOL; NANOCARRIER; NUCLEIC ACID; TRANSFERRIN RECEPTOR; ANTINEOPLASTIC AGENT; COLLOID; DRUG CARRIER; NANOPARTICLE;

ACUTE MYELOBLASTIC LEUKEMIA; BONE MARROW; CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; DRUG TARGETING; GENE SILENCING; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; CLINICAL TRIAL (TOPIC); COLLOID; LEUKEMIA, MYELOID, ACUTE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLLOIDS; DRUG CARRIERS; HUMANS; LEUKEMIA, MYELOID, ACUTE; NANOPARTICLES;

EID: 84964697352     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201016666150817095045     Document Type: Review

References (122)

1. Ofran, Y., Rowe, J.M. Genetic profiling in acute myeloid leukaemia ─ where are we and what is its role in patient management. Br. J. Haematol., 2013, 160(3), 303-320.
2. Gasiorowski, R.E., Clark, G.J., Bradstock, K., Hart, D.N.J. Antibody therapy for acute myeloid leukaemia. Br. J. Haematol., 2014, 164(4), 481-495.
3. Zhou, J., Chng, W.-J. Identification and targeting leukemia stem cells: the path to the cure for acute myeloid leukemia. World J. Stem Cells, 2014, 6(4), 473-484.
4. Testa, U., Pelosi, E., Frankel, A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark. Res., 2014, 2(1), 4.
5. Meadows, A.T., Friedman, D.L., Neglia, J.P., Mertens, A.C., Donaldson, S.S., Stovall, M., Hammond, S., Yasui, Y., Inskip, P.D. Second neoplasms in survivors of childhood cancer: findings from the childhood cancer survivor study cohort. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 2009, 27(14), 2356-2362.
6. Borgmann, A., Zinn, C., Hartmann, R., Herold, R., Kaatsch, P., Escherich, G., Möricke, A., Henze, G., von Stackelberg, A., ALLREZ BFM Study Group. Secondary malignant neoplasms after intensive treatments of relapsed acute lymphoblastic leukaemia in childhood. Eur. J. Cancer, 2008, 44(2), 257-268.
7. Fulbright, J.M., Raman, S., McClellan, W.S., August, K.J. Late effects of childhood leukemia therapy. Curr. Hematol. Malig. Rep., 2011, 6(3), 195-205.
8. Larson, R.A., Wernli, M., Beau, M.L., Daly, K.M., Pape, L.H., Rowley, J.D., Vardiman, J.W. Short remission durations in therapy- related leukemia despite cytogenetic complete responses to high-dose cytarabine. Blood, 1988, 72(4), 1333-1339.
9. Schoch, C., Kern, W., Schnittger, S., Hiddemann, W., Haferlach, T. Karyotype is an independent prognostic parameter in therapyrelated acute myeloid leukemia (t-AML): An analysis of 93 patients with t-aml in comparison to 1091 patients with de Novo AML. Leukemia, 2004, 18(1), 120-125.
10. Godley, L.A., Larson, R.A. Therapy-related myeloid leukemia. Semin. Oncol., 2008, 35(4), 418-429.
11. Appelbaum, F.R., Gundacker, H., Head, D.R., Slovak, M.L., Willman, C.L., Godwin, J.E., Anderson, J.E., Petersdorf, S.H. Age and acute myeloid leukemia. Blood, 2006, 107(9), 3481-3485.
12. Juliusson, G., Antunovic, P., Derolf, A., Lehmann, S., Möllgård, L., Stockelberg, D., Tidefelt, U., Wahlin, A., Höglund, M. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry. Blood, 2009, 113(18), 4179-4187.
13. Döhner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., Büchner, T., Burnett, A.K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R.A., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G.J., Sanz, M. A., Sierra, J., Tallman, M.S., Löwenberg, B., Bloomfield, C.D., European leukemianet. diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 2010, 115(3), 453-474.
14. Breems, D.A., Van Putten, W.L.J., Huijgens, P.C., Ossenkoppele, G.J., Verhoef, G.E.G., Verdonck, L.F., Vellenga, E., De Greef, G.E., Jacky, E., Van der Lelie, J., Boogaerts, M.A., Löwenberg, B. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J. Clin. Oncol., 2005, 23(9), 1969-1978.
15. Estey, E.H. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia, 2000, 14(3), 476-479.
16. Yates, J.W., Wallace, H.J., Ellison, R.R., Holland, J.F. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother. Rep., 1973, 57(4), 485-488.
17. Lichtman, M.A. A Historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3. Blood Cells. Mol. Dis., 2013, 50(2), 119-130.
18. Rowe, J.M. Important milestones in acute leukemia in 2013. Best Pract. Res. Clin. Haematol., 2013, 26(3), 241-244.
19. Fernandez, H.F., Sun, Z., Yao, X., Litzow, M.R., Luger, S.M., Paietta, E.M., Racevskis, J., Dewald, G.W., Ketterling, R.P., Bennett, J.M., Rowe, J.M., Lazarus, H.M., Tallman, M.S. Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J. Med., 2009, 361(13), 1249-1259.
20. Stein, A.S., O’Donnell, M.R., Slovak, M.L., Nademanee, A., Dagis, A., Schmidt, G.M., Parker, P.M., Snyder, D.S., Smith, E.P., Somlo, G., Margolin, K.A., Arber, D., Niland, J., Forman, S.J. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non m3 acute myelogenous leukemia: Impact of cytogenetics on achieving a complete remission. Leukemia, 2000, 14(7), 1191-1196.
21. Löwenberg, B., Ossenkoppele, G.J., van Putten, W., Schouten, H.C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., Biemond, B. J., Vellenga, E., van Marwijk Kooy, M., Verdonck, L.F., Beck, J., Döhner, H., Gratwohl, A., Pabst, T., Verhoef, G., Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON), German AML Study Group (AMLSG), Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia. N. Engl. J. Med., 2009, 361(13), 1235-1248.
22. Des Champs-Bro, B., Leroy-Cotteau, A., Mazingue, F., Pasquier, F., François, N., Corm, S., Lemaitre, L., Poulain, D., Yakoub- Agha, I., Alfandari, S., Sendid, B. Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in oncohaematology. J. Clin. Pharm. Ther., 2011, 36(2), 152-160.
23. Kurosawa, M., Yonezumi, M., Hashino, S., Tanaka, J., Nishio, M., Kaneda, M., Ota, S., Koda, K., Suzuki, N., Yoshida, M., Hirayama, Y., Takimoto, R., Torimoto, Y., Mori, A., Takahashi, T., Iizuka, S., Ishida, T., Kobayashi, R., Oda, T., Sakai, H., Yamamoto, S., Takahashi, F., Fukuhara, T. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int. J. Hematol., 2012, 96(6), 748-757.
24. Slobbe, L., Polinder, S., Doorduijn, J.K., Lugtenburg, P.J., el Barzouhi, A., Steyerberg, E. W., Rijnders, B.J.A. Outcome and Medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 2008, 47(12), 1507-1512.
25. Syrjälä, H., Ohtonen, P., Kinnunen, U., Räty, R., Elonen, E., Nousiainen, T., Jantunen, E., Remes, K., Itälä-Remes, M., Silvennoinen, R., Koistinen, P., Finnish Leukemia Group. Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: Treatment cycle matters. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol., 2010, 29(10), 1211-1218.
26. Fan, C.Q., Crawford, J.M. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J. Clin. Exp. Hepatol., 2014, 4(4), 332-346.
27. Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, M.L., Berger, M.S., Eten, C.B., Loken, M.R., van Dongen, J.J., Bernstein, I.D., Appelbaum, F.R., Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol., 2001, 19(13), 3244-3254.
28. Amrein, P.C., Davis, R.B., Mayer, R.J., Schiffer, C.A. Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: A CALGB phase I study. Am. J. Hematol., 1990, 35(2), 80-83.
29. Al-Ali, H.K., Jaekel, N., Junghanss, C., Maschmeyer, G., Krahl, R., Cross, M., Hoppe, G., Niederwieser, D. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: A multicenter phase I/II. Leuk. Lymphoma, 2012, 53(1), 110-117.
30. Sudan, N., Rossetti, J.M., Shadduck, R.K., Latsko, J., Lech, J.A., Kaplan, R.B., Kennedy, M., Gryn, J.F., Faroun, Y., Lister, J. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer, 2006, 107(8), 1839-1843.
31. Cashen, A.F., Schiller, G.J., O’Donnell, M.R., DiPersio, J.F. Multicenter, Phase II Study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J. Clin. Oncol., 2010, 28(4), 556-561.
32. Issa, J.-P., Garcia-Manero, G., Huang, X., Cortes, J., Ravandi, F., Jabbour, E., Borthakur, G., Brandt, M., Pierce, S., Kantarjian, H.M. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer, 2015, 121(4), 556-561.
33. Freund, M., Link, H., Diedrich, H., LeBlanc, S., Wilke, H.J., Poliwoda, H. High-Dose Ara-C and Etoposide in Refractory or Relapsing Acute Leukemia. Cancer Chemother. Pharmacol., 1991, 28(6), 487-490.
34. Archimbaud, E., Troncy, J., Sebban, C., Guyotat, D., Devaux, Y., French, M., Moriceau, M., Viala, J.J., Fiere, D. Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia. Cancer Chemother. Pharmacol., 1989, 25(3), 223-225.
35. Lejeune, C., Tubiana, N., Gastaut, J. A., Maraninchi, D., Richard, B., Launay, M. C., Sainty, D., Sebahoun, G., Carcassonne, Y. High-dose cytosine arabinoside and mitoxantrone in previouslytreated acute leukemia patients. Eur. J. Haematol., 1990, 44(4), 240-243.
36. Meloni, G., Vignetti, M., Andrizzi, C., Capria, S., Foa, R., Mandelli, F. Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: Updated experience with 20 cases. Leuk. Lymphoma, 1996, 21(5-6), 429-435.
37. Chaoui, D., Peffault De Latour, R., Legrand, O., Marie, J.-P. Acute myeloid leukemia in the elderly: Etoposide when anthracyclins are contraindicated. Leuk. Lymphoma, 2005, 46(3), 401-404.
38. Montalban-Bravo, G., Garcia-Manero, G. Novel drugs for older patients with acute myeloid leukemia. Leukemia, 2014, 29(4), 760-769.
39. Amadori, S., Suciu, S., Willemze, R., Mandelli, F., Selleslag, D., Stauder, R., Ho, A., Denzlinger, C., Leone, G., Fabris, P., Muus, P., Vignetti, M., Hagemeijer, A., Beeldens, F., Anak, O., De Witte, T., EORTC leukemia group, GIMEMA leukemia group. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: A Phase II Study (AML-15) of the EORTC and GIMEMA Leukemia Groups. Haematologica 2004, 89(8), 950-956.
40. Löwenberg, B., Beck, J., Graux, C., Putten, W. van, Schouten, H.C., Verdonck, L.F., Ferrant, A., Sonneveld, P., Jongen- Lavrencic, M., Lilienfeld-Toal, M. von, Biemond, B.J., Vellenga, E., Breems, D., Muijnck, H. de, Schaafsma, R., Verhoef, G., Döhner, H., Gratwohl, A., Pabst, T., Ossenkoppele, G.J., Maertens, J., (hovon), for the D.-B. H.-O. C. G., (amlsg), G. A. A. S. G., (sakk), S. G. for C. C. R. C. G. Gemtuzumab ozogamicin as postremission treatment in aml at 60 years of age or more: Results of a multicenter phase 3 study. Blood, 2010, 115(13), 2586-2591.
41. Chevallier, P., Delaunay, J., Turlure, P., Pigneux, A., Hunault, M., Garand, R., Guillaume, T., Avet-Loiseau, H., Dmytruk, N., Girault, S., Milpied, N., Ifrah, N., Mohty, M., Harousseau, J.-L. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) Primary resistant or relapsed acute myeloid leukemia. J. Clin. Oncol., 2008, 26(32), 5192-5197.
42. Chauncey, T.R. Drug resistance mechanisms in acute leukemia. Curr. Opin. Oncol., 2001, 13(1), 21-26.
43. Guo, J., Cahill, M.R., McKenna, S.L., O’Driscoll, C.M. Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia. Biotechnol. Adv., 2014, 32(8), 1396-1409.
44. Couvreur, P. Nanoparticles in drug delivery: Past, present and future. Adv. Drug Deliv. Rev., 2013, 65(1), 21-23.
45. Fan, Y., Zhang, Q. Development of liposomal formulations: From concept to clinical investigations. Asian J. Pharm. Sci., 2013, 8(2), 81-87.
46. Woodle, N. Controlling liposome blood clearance by surfacegrafted polymers. Adv. Drug Deliv. Rev., 1998, 32(1-2), 139-152.
47. Jain, R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev., 1987, 6(4), 559-593.
48. Oyen, W.J., Boerman, O.C., Storm, G., van Bloois, L., Koenders, E.B., Crommelin, D.J., van der Meer, J.W., Corstens, F.H. Labelled stealth liposomes in experimental infection: An alternative to leukocyte scintigraphy? Nucl. Med. Commun., 1996, 17(9), 742-748.
49. Maruyama, K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv. Drug Deliv. Rev., 2011, 63(3), 161-169.
50. Moghimi, S.M. Exploiting bone marrow microvascular structure for drug delivery and future therapies. Adv. Drug Deliv. Rev., 1995, 17(1), 61-73.
51. Awasthi, V.D., Garcia, D., Goins, B.A., Phillips, W.T. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int. J. Pharm., 2003, 253(1-2), 121-132.
52. Gibaud, S., Demoy, M., Andreux, J.P., Weingarten, C., Gouritin, B., Couvreur, P. Cells involved in the capture of nanoparticles in hematopoietic organs. J. Pharm. Sci., 1996, 85(9), 944-950.
53. Sahay, G., Alakhova, D.Y., Kabanov, A.V. Endocytosis of nanomedicines. J. Control. Release, 2010, 145(3), 182-195.
54. Sou, K., Goins, B., Takeoka, S., Tsuchida, E., Phillips, W.T. Selective uptake of surface-modified phospholipid vesicles by bone marrow macrophages in vivo. Biomaterials, 2007, 28(16), 2655-2666.
55. Sou, K., Goins, B., Oyajobi, B.O., Travi, B.L., Phillips, W.T. Bone marrow-targeted liposomal carriers. Expert Opin. Drug Deliv., 2011, 8(3), 317-328.
56. Paszko, E., Senge, M.O. Immunoliposomes. Curr. Med. Chem., 2012, 19(31), 5239-5277.
57. Nielsen, U.B., Kirpotin, D.B., Pickering, E.M., Hong, K., Park, J.W., Refaat, S.M., Shao, Y., Benz, C.C., Marks, J.D. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta, 2002, 1591(1-3), 109-118.
58. Senzer, N., Nemunaitis, J., Nemunaitis, D., Bedell, C., Edelman, G., Barve, M., Nunan, R., Pirollo, K.F., Rait, A., Chang, E.H. Phase I Study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol. Ther. J. Am. Soc. Gene Ther., 2013, 21(5), 1096-1103.
59. Farokhzad, O.C., Cheng, J., Teply, B.A., Sherifi, I., Jon, S., Kantoff, P.W., Richie, J.P., Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA, 2006, 103(16), 6315-6320.
60. Stella, B., Arpicco, S., Peracchia, M. T., Desmaële, D., Hoebeke, J., Renoir, M., D’Angelo, J., Cattel, L., Couvreur, P. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci., 2000, 89(11), 1452-1464.
61. Myhren, L., Nilssen, I.M., Nicolas, V., Døskeland, S.O., Barratt, G., Herfindal, L. Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia. Eur. J. Pharm. Biopharm., 2014, 88(1), 186-193.
62. Yu, B., Zhao, X., Lee, L.J., Lee, R.J. Targeted delivery systems for oligonucleotide therapeutics. AAPS J., 2009, 11(1), 195-203.
63. Wang, F., Chen, L., Zhang, R., Chen, Z., Zhu, L. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer. J. Control. Release, 2014, 196, 222-233.
64. Sakurai, Y., Hatakeyama, H., Sato, Y., Hyodo, M., Akita, H., Ohga, N., Hida, K., Harashima, H. RNAi-mediated gene knockdown and anti-angiogenic therapy of rccs using a cyclic rgdmodified liposomal-siRNA system. J. Control. Release, 2014, 173, 110-118.
65. Ahsan, F., Rivas, I.P., Khan, M.A., Torres Suárez, A.I. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Control. Release, 2002, 79(1-3), 29-40.
66. Ross, J.F., Wang, H., Behm, F.G., Mathew, P., Wu, M., Booth, R., Ratnam, M. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer, 1999, 85(2), 348-357.
67. Pan, X.Q., Zheng, X., Shi, G., Wang, H., Ratnam, M., Lee, R.J. Strategy for the treatment of acute myelogenous leukemia based on folate receptor β-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood, 2002, 100(2), 594-602.
68. Li, H., Lu, Y., Piao, L., Wu, J., Liu, S., Marcucci, G., Ratnam, M., Lee, R.J. Targeting human clonogenic acute myelogenous leukemia cells via folate conjugated liposomes combined with receptor modulation by all-trans retinoic acid. Int. J. Pharm., 2010, 402(1- 2), 57-63.
69. Clarhaut, J., Fraineau, S., Guilhot, J., Peraudeau, E., Tranoy- Opalinski, I., Thomas, M., Renoux, B., Randriamalala, E., Bois, P., Chatelier, A., Monvoisin, A., Cronier, L., Papot, S., Guilhot, F. A galactosidase-responsive doxorubicin-folate conjugate for selective targeting of acute myelogenous leukemia blasts. Leuk. Res., 2013, 37(8), 948-955.
70. Varshosaz, J., Hassanzadeh, F., Sadeghi Aliabadi, H., Nayebsadrian, M., Banitalebi, M., Rostami, M. Synthesis and characterization of folate-targeted dextran/retinoic acid micelles for doxorubicin delivery in acute leukemia. BioMed Res. Int., 2014, 2014, 525684.
71. Liu, M., Li, W., Larregieu, C.A., Cheng, M., Yan, B., Chu, T., Li, H., Mao, S. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity. Mol. Pharm., 2014, 11(7), 2305-2312.
72. Cecco, S., Aliberti, M., Baldo, P., Giacomin, E., Leone, R. Safety and efficacy evaluation of albumin-bound paclitaxel. Expert Opin. Drug Saf., 2014, 13(4), 511-520.
73. Barenholz, Y. Doxil®--the First FDA-approved nano-drug: Lessons learned. J. Control. Release, 2012, 160(2), 117-134.
74. Airoldi, M., Amadori, D., Barni, S., Cinieri, S., De Placido, S., Di Leo, A., Gennari, A., Iacobelli, S., Ionta, M.T., Lorusso, V., Lotrionte, M., Marchetti, P., Mattioli, R., Minotti, G., Pronzato, P., Rosti, G., Tondini, C.A., Veronesi, A. Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: A synthetic review. Tumori, 2011, 97(6), 690-692.
75. Sempkowski, M., Locke, T., Stras, S., Zhu, C., Sofou, S. Liposome-based approaches for delivery of mainstream chemotherapeutics: Preparation Methods, liposome designs, therapeutic efficacy. Crit. Rev. Oncog., 2014, 19(3-4), 177-221.
76. Jafari, M., Soltani, M., Naahidi, S., Karunaratne, D.N., Chen, P. Nonviral approach for targeted nucleic acid delivery. Curr. Med. Chem., 2012, 19(2), 197-208.
77. Fattal, E., Barratt, G. Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br. J. Pharmacol., 2009, 157(2), 179-194.
78. Ferreira, D.D.S., Lopes, S.C. de A., Franco, M.S., Oliveira, M.C. pH-Sensitive liposomes for drug delivery in cancer treatment. Ther. Deliv., 2013, 4(9), 1099-1123.
79. Bouclier, C., Marsaud, V., Bawa, O., Nicolas, V., Moine, L., Opolon, P., Renoir, J.-M. Coadministration of nanosystems of short silencing RNAS targeting oestrogen receptor alpha and antioestrogen synergistically induces tumour growth inhibition in human breast cancer xenografts. Breast Cancer Res. Treat., 2010, 122(1), 145-158.
80. Tabernero, J., Shapiro, G.I., LoRusso, P.M., Cervantes, A., Schwartz, G.K., Weiss, G.J., Paz-Ares, L., Cho, D.C., Infante, J.R., Alsina, M., Gounder, M.M., Falzone, R., Harrop, J., White, A.C.S., Toudjarska, I., Bumcrot, D., Meyers, R.E., Hinkle, G., Svrzikapa, N., Hutabarat, R.M., Clausen, V.A., Cehelsky, J., Nochur, S.V., Gamba-Vitalo, C., Vaishnaw, A.K., Sah, D.W.Y., Gollob, J.A., Burris, H.A. First-in-Humans Trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov., 2013, 3(4), 406-417.
81. Lu, C., Stewart, D.J., Lee, J.J., Ji, L., Ramesh, R., Jayachandran, G., Nunez, M.I., Wistuba, I.I., Erasmus, J.J., Hicks, M.E., Grimm, E.A., Reuben, J.M., Baladandayuthapani, V., Templeton, N.S., McMannis, J.D., Roth, J.A. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PloS One, 2012, 7(4), e34833.
82. Garzon, R., Liu, S., Fabbri, M., Liu, Z., Heaphy, C.E.A., Callegari, E., Schwind, S., Pang, J., Yu, J., Muthusamy, N., Havelange, V., Volinia, S., Blum, W., Rush, L.J., Perrotti, D., Andreeff, M., Bloomfield, C.D., Byrd, J.C., Chan, K., Wu, L.-C., Croce, C.M., Marcucci, G. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood, 2009, 113(25), 6411-6418.
83. Huang, X., Schwind, S., Yu, B., Santhanam, R., Wang, H., Hoellerbauer, P., Mims, A., Klisovic, R., Walker, A.R., Chan, K.K., Blum, W., Perrotti, D., Byrd, J.C., Bloomfield, C.D., Caligiuri, M.A., Lee, R.J., Garzon, R., Muthusamy, N., Lee, L.J., Marcucci, G. Targeted delivery of microRNA-29b by transferrinconjugated anionic lipopolyplex nanoparticles: A novel therapeutic strategy in acute myeloid leukemia. Clin. Cancer Res., 2013, 19(9), 2355-2367.
84. Lee, Y., Vassilakos, A., Feng, N., Lam, V., Xie, H., Wang, M., Jin, H., Xiong, K., Liu, C., Wright, J., Young, A. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res., 2003, 63(11), 2802-2811.
85. Klisovic, R.B., Blum, W., Wei, X., Liu, S., Liu, Z., Xie, Z., Vukosavljevic, T., Kefauver, C., Huynh, L., Pang, J., Zwiebel, J.A., Devine, S., Byrd, J.C., Grever, M.R., Chan, K., Marcucci, G. Phase I Study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Clin. Cancer Res., 2008, 14(12), 3889-3895.
86. Jin, Y., Liu, S., Yu, B., Golan, S., Koh, C.-G., Yang, J., Huynh, L., Yang, X., Pang, J., Muthusamy, N., Chan, K.K., Byrd, J.C., Talmon, Y., Lee, L.J., Lee, R.J., Marcucci, G. Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pHsensitive lipopolyplex nanoparticles: A novel oligonucleotidebased therapeutic strategy in acute myeloid leukemia. Mol. Pharm., 2010, 7(1), 196-206.
87. Gul-Uludağ, H., Valencia-Serna, J., Kucharski, C., Marquez- Curtis, L.A., Jiang, X., Larratt, L., Janowska-Wieczorek, A., Uludağ, H. Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells. Leuk. Res., 2014, 38(11), 1299-1308.
88. He, W., Bennett, M.J., Luistro, L., Carvajal, D., Nevins, T., Smith, M., Tyagi, G., Cai, J., Wei, X., Lin, T.-A., Heimbrook, D.C., Packman, K., Boylan, J.F. Discovery of siRNA Lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability. Mol. Ther., 2014, 22(2), 359-370.
89. Dicko, A., Kwak, S., Frazier, A.A., Mayer, L.D., Liboiron, B.D. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Int. J. Pharm., 2010, 391(1-2), 248-259.
90. Tardi, P., Johnstone, S., Harasym, N., Xie, S., Harasym, T., Zisman, N., Harvie, P., Bermudes, D., Mayer, L. In vivo maintenance of synergistic cytarabine: Daunorubicin ratios greatly enhances therapeutic efficacy. Leuk. Res., 2009, 33(1), 129-139.
91. Gausdal, G., Gjertsen, B.T., McCormack, E., Van Damme, P., Hovland, R., Krakstad, C., Bruserud, Ø., Gevaert, K., Vandekerckhove, J., Døskeland, S.O. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood, 2008, 111(5), 2866-2877.
92. Tan, K.-B., Ling, L.-U., Bunte, R.M., Chng, W.-J., Chiu, G.N.C. Liposomal codelivery of a synergistic combination of bioactive lipids in the treatment of acute myeloid leukemia. Nanomed., 2014, 9(11), 1665-1679.
93. Annino, L., Chierichini, A., Anaclerico, B., Finolezzi, E., Norata, M., Cortese, S., Cassetta, M. I., Fallani, S., Novelli, A., Girmenia, C. Prospective phase II Single-center study of the safety of a single very high dose of liposomal amphotericin b for antifungal prophylaxis in patients with acute myeloid leukemia. Antimicrob. Agents Chemother., 2013, 57(6), 2596-2602.
94. Su, F.-Y., Chuang, E.-Y., Lin, P.-Y., Chou, Y.-C., Chen, C.-T., Mi, F.-L., Wey, S.-P., Yen, T.-C., Lin, K.-J., Sung, H.-W. Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles. Biomaterials, 2014, 35(11), 3641-3649.
95. Choi, E.W., Koo, H.C., Shin, I.S., Chae, Y.J., Lee, J.H., Han, S.M., Lee, S.J., Bhang, D.H., Park, Y.H., Lee, C.W., Youn, H.Y. Preventive and therapeutic effects of gene therapy using silica nanoparticles- binding of gm-csf gene on white blood cell production in dogs with leukopenia. Exp. Hematol., 2008, 36(9), 1091-1097.
96. Fassas, A., Buffels, R., Kaloyannidis, P., Anagnostopoulos, A. Safety of high-dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia. Br. J. Haematol., 2003, 122(1), 161-163.
97. Litzow, M.R., Othus, M., Cripe, L.D., Gore, S.D., Lazarus, H.M., Lee, S.J., Bennett, J.M., Paietta, E.M., Dewald, G.W., Rowe, J.M., Tallman, M.S., for the Eastern Cooperative Oncology Group Leukemia Committee. Failure of Three Novel Regimens to Improve Outcome for Patients with Relapsed or Refractory Acute Myeloid Leukaemia: A Report from the Eastern Cooperative Oncology Group. Br. J. Haematol., 2010, 148(2), 217-225.
98. Kaspers, G.J.L., Zimmermann, M., Reinhardt, D., Gibson, B.E. ., Tamminga, R.Y.J., Aleinikova, O., Armendariz, H., Dworzak, M., Ha, S.-Y., Hasle, H., Hovi, L., Maschan, A., Bertrand, Y., Leverger, G.G., Razzouk, B.I., Rizzari, C., Smisek, P., Smith, O., Stark, B., Creutzig, U. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the international BFM study group. J. Clin. Oncol., 2013, 31(5), 599-607.
99. Creutzig, U., Zimmermann, M., Bourquin, J.-P., Dworzak, M.N., Fleischhack, G., Graf, N., Klingebiel, T., Kremens, B., Lehrnbecher, T., von Neuhoff, C., Ritter, J., Sander, A., Schrauder, A., von Stackelberg, A., Stary, J., Reinhardt, D. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from study AML-BFM 2004. Blood, 2013, 122(1), 37-43.
100. Feldman, E.J., Kolitz, J.E., Trang, J.M., Liboiron, B.D., Swenson, C.E., Chiarella, M.T., Mayer, L.D., Louie, A.C., Lancet, J.E. Pharmacokinetics of CPX-351, a nano-scale liposomal fixed molar ratio formulation of cytarabine: Daunorubicin, in patients with advanced leukemia. Leuk. Res., 2012, 36(10), 1283-1289.
101. Feldman, E.J., Lancet, J.E., Kolitz, J.E., Ritchie, E.K., Roboz, G.J., List, A.F., Allen, S.L., Asatiani, E., Mayer, L.D., Swenson, C., Louie, A.C. First-In-Man Study of CPX-351: A liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 Molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J. Clin. Oncol., 2011, 29(8), 979-985.
102. Lancet, J.E., Cortes, J.E., Hogge, D.E., Tallman, M.S., Kovacsovics, T.J., Damon, L.E., Komrokji, R., Solomon, S.R., Kolitz, J.E., Cooper, M., Yeager, A.M., Louie, A.C., Feldman, E.J. Phase 2 trial of CPX-351, a Fixed 5:1 Molar Ratio of Cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood, 2014, 123(21), 3239-3246.
103. Liposomal cytarabine-daunorubicin CPX-351 in treating patients with untreated myelodysplastic syndrome or acute myeloid leukemia. clinicaltrials.gov/ct2/show/NCT01804101 (Accessed Mar 29, 2015).
104. Carol, H., Fan, M.M.Y., Harasym, T.O., Boehm, I., Mayer, L.D., Houghton, P., Smith, M.A., Lock, R.B. Efficacy of CPX-351, (cytarabine: daunorubicin) Liposome injection, against acute lymphoblastic leukemia (all) xenograft models of the pediatric preclinical testing program. Pediatr. Blood Cancer, 2015, 62(1), 65-71.
105. Reikvam, H., Nepstad, I., Sulen, A., Gjertsen, B.T., Hatfield, K.J., Bruserud, Ø. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opin. Investig. Drugs, 2013, 22(5), 551-563.
106. Audisio, D., Methy-Gonnot, D., Radanyi, C., Renoir, J.-M., Denis, S., Sauvage, F., Vergnaud-Gauduchon, J., Brion, J.-D., Messaoudi, S., Alami, M. Synthesis and antiproliferative activity of novobiocin analogues as potential HSP90 inhibitors. Eur. J. Med. Chem., 2014, 83, 498-507.
107. Urbinati, G., Marsaud, V., Nicolas, V., Vergnaud-Gauduchon, J., Renoir, J.-M. Liposomal Trichostatin A: Therapeutic potential in hormone-dependent and -independent breast cancer xenograft models. Horm. Mol. Biol. Clin. Investig., 2011, 6(2), 215-225.
108. De Verdière, A.C., Dubernet, C., Némati, F., Soma, E., Appel, M., Ferté, J., Bernard, S., Puisieux, F., Couvreur, P. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: Towards a mechanism of action. Br. J. Cancer, 1997, 76(2), 198-205.
109. Galmarini, C.M., Warren, G., Senanayake, M.T., Vinogradov, S.V. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs. Int. J. Pharm., 2010, 395(1-2), 281-289.
110. Yu, B., Mao, Y., Yuan, Y., Yue, C., Wang, X., Mo, X., Jarjoura, D., Paulaitis, M.E., Lee, R.J., Byrd, J.C., Lee, L.J., Muthusamy, N. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. Biomaterials, 2013, 34(26), 6185-6193.
111. Peled, A., Tavor, S. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics, 2013, 3(1), 34-39.
112. Uy, G.L., Rettig, M.P., Motabi, I.H., McFarland, K., Trinkaus, K.M., Hladnik, L.M., Kulkarni, S., Abboud, C.N., Cashen, A.F., Stockerl-Goldstein, K.E., Vij, R., Westervelt, P., DiPersio, J.F. A Phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood, 2012, 119(17), 3917-3924.
113. Martina, M.-S., Fortin, J.-P., Ménager, C., Clément, O., Barratt, G., Grabielle-Madelmont, C., Gazeau, F., Cabuil, V., Lesieur, S. Generation of superparamagnetic liposomes revealed as highly efficient mri contrast agents for in vivo imaging. J. Am. Chem. Soc., 2005, 127(30), 10676-10685.
114. Rivière, C., Martina, M.-S., Tomita, Y., Wilhelm, C., Tran Dinh, A., Ménager, C., Pinard, E., Lesieur, S., Gazeau, F., Seylaz, J. Magnetic targeting of nanometric magnetic fluid loaded liposomes to specific brain intravascular areas: A dynamic imaging study in mice. Radiology, 2007, 244(2), 439-448.
115. Hayashi, K., Nakamura, M., Miki, H., Ozaki, S., Abe, M., Matsumoto, T., Sakamoto, W., Yogo, T., Ishimura, K. Magnetically responsive smart nanoparticles for cancer treatment with a combination of magnetic hyperthermia and remote-control drug release. Theranostics, 2014, 4(8), 834-844.
116. Cardinal, J., Klune, J. R., Chory, E., Jeyabalan, G., Kanzius, J. S., Nalesnik, M., Geller, D.A. Noninvasive radiofrequency ablation of cancer targeted by gold nanoparticles. Surgery, 2008, 144(2), 125-132.
117. Jensen, S.S., Andresen, T.L., Davidsen, J., Høyrup, P., Shnyder, S.D., Bibby, M.C., Gill, J.H., Jørgensen, K. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. Mol. Cancer Ther., 2004, 3(11), 1451-1458.
118. Zhu, L., Kate, P., Torchilin, V.P. Matrix metalloprotease 2- responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano, 2012, 6(4), 3491-3498.
119. Mortensen, B.T., Jensen, P.O., Helledie, N., Iversen, P.O., Ralfkiaer, E., Larsen, J.K., Madsen, M.T. Changing bone marrow microenvironment during development of acute myeloid leukaemia in rats. Br. J. Haematol., 1998, 102(2), 458-464.
120. Simard, P., Leroux, J.-C. In vivo evaluation of ph-sensitive polymer- based immunoliposomes targeting the CD33 antigen. Mol. Pharm., 2010, 7(4), 1098-1107.
121. Wang, Y., Wang, H., Lv, X., Liu, C., Qi, L., Song, X., Yu, A. Enhancement of all-trans retinoic acid-induced differentiation by pH-Sensitive nanoparticles for solid tumor cells. Macromol. Biosci., 2014, 14(3), 369-379.
122. Basha, R., Sabnis, N., Heym, K., Bowman, W.P., Lacko, A.G. Targeted nanoparticles for pediatric leukemia therapy. Front. Oncol., 2014, 4.